Legacy Wealth Management (Idaho)’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-159
Closed -$10.3K – 507
2026
Q1
$10.3K Hold
159
– – 0.01% 482
2025
Q4
$10.7K Buy
159
+44
+38% +$2.96K 0.01% 416
2025
Q3
$8.44K Hold
115
– – ﹤0.01% 368
2025
Q2
$5.98K Sell
115
-20
-15% -$1.14K ﹤0.01% 374
2025
Q1
$8.62K Hold
135
– – 0.01% 357
2024
Q4
$7.71K Buy
135
+20
+17% +$1.03K ﹤0.01% 329
2024
Q3
$6.74K Buy
+115
New +$6.59K ﹤0.01% 361

Other funds holding HALO

Legacy Wealth Management (Idaho)'s HALO Position: Q2 2026 in Review

Legacy Wealth Management (Idaho) sold out of Halozyme (HALO) in Q2 2026, closing a stake of 159 shares — an estimated $10.3K sold.

Legacy Wealth Management (Idaho) first reported a position in HALO in Q3 2024 and held it in 7 quarters. The position peaked at $10.7K in Q4 2025. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Legacy Wealth Management (Idaho) reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 159 Halozyme shares in Q2 2026, an estimated $10.3K.
  • Legacy Wealth Management (Idaho) first reported a position in Halozyme in Q3 2024 and held it in 7 quarters.
  • Legacy Wealth Management (Idaho)'s Halozyme position peaked at $10.7K in Q4 2025.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q2 2026, filed 13 Aug 2026.